We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Three new IL-23 inhibitors have been approved for IBD, ...

A study found low rates of cancer recurrence, progression, or new malignancy among patients with psoriasis and prior neoplasia receiving interleukin-23 (IL-23) inhibitors. Researchers conducted a ...

Please provide your email address to receive an email when new articles are posted on . Treatment options for patients with inflammatory bowel disease — particularly in the anti-interleukin-23 space — ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...